- Home
- VSTM vs IKNA Comparison
VSTM vs IKNA Comparison
Compare VSTM & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- IKNA
- Stock Information
- Founded
- VSTM 2010
- IKNA 2016
- Country
- VSTM United States
- IKNA United States
- Employees
- VSTM N/A
- IKNA N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- IKNA Health Care
- Exchange
- VSTM Nasdaq
- IKNA Nasdaq
- Market Cap
- VSTM 132.0M
- IKNA 83.0M
- IPO Year
- VSTM 2012
- IKNA 2021
- Fundamental
- Price
- VSTM $3.88
- IKNA $1.68
- Analyst Decision
- VSTM Strong Buy
- IKNA Buy
- Analyst Count
- VSTM 8
- IKNA 2
- Target Price
- VSTM $14.57
- IKNA $3.00
- AVG Volume (30 Days)
- VSTM 1.1M
- IKNA 41.6K
- Earning Date
- VSTM 11-06-2024
- IKNA 11-07-2024
- Dividend Yield
- VSTM N/A
- IKNA N/A
- EPS Growth
- VSTM N/A
- IKNA N/A
- EPS
- VSTM N/A
- IKNA N/A
- Revenue
- VSTM $10,000,000.00
- IKNA $1,844,000.00
- Revenue This Year
- VSTM N/A
- IKNA N/A
- Revenue Next Year
- VSTM $125.69
- IKNA N/A
- P/E Ratio
- VSTM N/A
- IKNA N/A
- Revenue Growth
- VSTM N/A
- IKNA N/A
- 52 Week Low
- VSTM $2.10
- IKNA $1.02
- 52 Week High
- VSTM $14.22
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- VSTM 63.77
- IKNA 51.57
- Support Level
- VSTM $3.11
- IKNA $1.68
- Resistance Level
- VSTM $3.76
- IKNA $1.78
- Average True Range (ATR)
- VSTM 0.33
- IKNA 0.04
- MACD
- VSTM 0.04
- IKNA 0.00
- Stochastic Oscillator
- VSTM 94.26
- IKNA 36.36
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.